News
Why Pan American Silver, Chefs' Warehouse, and Perrigo Jumped Today
Thursday was one of the worst sessions that the stock market has seen in several months, with major benchmarks falling 1% or more. Investors are growing increasingly nervous about the rising tensions
Here's Why Perrigo Company Rose as Much as 20.5% Today
Shares of Perrigo Company (NYSE: PRGO) rose over 20% this morning after the healthcare leader released second-quarter 2017 financial results and adjusted full-year 2017 guidance. While revenue slipped
5 Reasons Valeant's Situation Could Get Worse
Valeant Pharmaceuticals (NYSE: VRX) announced some good news in its second-quarter update on Tuesday. The drugmaker now expects to cut its debt by $5 billion sooner than its previous target of
Earnings Hangover Sacks Valeant Pharmaceuticals' Stock, Sending Shares Down 10%
Shares of embattled drugmaker Valeant Pharmaceuticals (NYSE: VRX) are pulling an about-face after initially moving higher following the release of its second-quarter earnings results before the
The Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July
Shares of Amicus Therapeutics (NASDAQ: FOLD), a biopharmaceutical company focused on the development rare-disease drugs, exploded higher by 29% during the month of July, according to data from S&P
The 1 Very Clear Reason Arena Pharmaceuticals, Inc. Skyrocketed 41% in July
Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a biopharmaceutical company focused on the development of small-molecule drugs for the treatment of a variety of diseases, catapulted 41% during July
Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today
In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous
Finally! 3 Figures From Valeant's Second-Quarter Report That Demonstrate Improvement
If you've ever played the board game Chutes and Ladders and landed on space 87, which throws the player back 63 spaces, you might have some idea of what it's been like to be a Valeant Pharmaceuticals
Paion präsentiert Halbjahreszahlen – Überraschungen bleiben aus
Das Biotech-Unternehmen Paion hat heute die mit Spannung erwarteten Zahlen für die erste Jahreshälfte 2017 vorgelegt. Die aber schnell nachließ, denn wirklich Überraschendes wurde nicht....
Why Amedisys Shares Slumped 24.6% in July
Amedisys Inc. (NASDAQ: AMED) shares lost nearly 25% of their value last month, according to S&P Global Market Intelligence. The drop was caused by word that the the federal government's Centers for
Why Tenet Healthcare Shares Dropped 14.4% Today
After reporting second-quarter earnings and offering up guidance for 2017, shares of Tenet Healthcare (NYSE: THC) have fallen 14.6% as of 2:30 p.m. EDT on Tuesday.Tenet Healthcare's year-over-year
Why Avis Budget Group, Depomed, and Tenet Healthcare Slumped Today
Investors saw the end of a historic bullish streak for stocks on Tuesday, as the Dow Jones Industrials failed in their bid for a 10th straight day of record-setting gains. Instead, major benchmarks
MyoKardia Inc. Is on the Rise Again Today -- Here's Why
After a monster run-up on Monday, MyoKardia Inc. (NASDAQ: MYOK) climbed another 145.9% as of 3:30 p.m. during Tuesday's session. It seems investors still giddy about positive clinical trial data
Why FibroGen Inc Skyrocketed Higher Today
FibroGen (NASDAQ: FGEN) is up nearly 50% at 1:10 p.m. Tuesday after releasing positive data from its phase 2 trial testing pamrevlumab in patients with a lung disease called idiopathic pulmonary
Here's Why Valeant Pharmaceuticals Intl. Inc. Surged as Much as 10%
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's traditionally grown through acquisitions and price hikes over the years, surged as much as 10% during Tuesday's trading
Valeant Pharmaceuticals' Debt Reduction Overshadows Drop in Revenue
One major question Valeant Pharmaceuticals (NYSE: VRX) had to answer when the company reported its second-quarter results was this: How significant was the impact of loss of exclusivity for....
Valeant Pharmaceuticals' Debt Reduction Overshadows Drop in Revenue
One major question Valeant Pharmaceuticals (NYSE: VRX) had to answer when the company reported its second-quarter results was this: How significant was the impact of loss of exclusivity for several of
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
When GW Pharmaceuticals (NASDAQ: GWPH) announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. There were at least
Emergent Biosolutions Inc Diversifies Its Revenue
One knock on Emergent Biosolutions (NYSE: EBS) has always been its dependence on anthrax vaccine BioThrax, but management made good on its promise to diversify, moving toward its goal of having $1
The 2 Most Important Figures in Valeant's Second-Quarter Report (and Neither Is EPS or Debt)
Earnings season remains in full swing, and tomorrow morning, one of the most popular and embattled drugmakers in the entire market is set to reports its second-quarter results.Valeant Pharmaceuticals
Here's Why Myokardia Inc. Stock Shot Up Today
Shares of Myokardia Inc. (NASDAQ: MYOK), a clinical-stage biotech developing treatments for inherited heart problems, took flight this morning. Positive data for its lead candidate propelled the stock
Why Horizon Pharma plc Stock Is Rising Today
Horizon Pharma (NASDAQ: HZNP), a specialty pharma company, saw its shares rise by as much as 21% in pre-market trading today. The drugmaker's stock is rising in response to a better-than-expected
Why You Shouldn't Fear Spark Therapeutics' Upcoming Share Issue
Having your shares in a company heavily diluted by a big secondary share issue is often scary for investors. It's easy to see why; if a company dumps a bucket of new stock on the market, existing
3 Things You'll Want to Watch in Valeant Pharmaceuticals' Q2 Results
Good news from Valeant Pharmaceuticals (NYSE: VRX)?That's what investors got the last time the drugmaker announced its quarterly results. Valeant posted a profit in the first quarter. Its balance
Why GW Pharmaceuticals Could Be a Gold Mine for Growth Investors
You've probably heard of the great California gold rush of the mid-19th century. Today, many are flocking to what has been called the "green rush" -- a major wave of money flowing into the marijuana